Bempedoic acid/ezetimibe

Bempedoic acid/ezetimibe
Combination of
Bempedoic acidAdenosine triphosphate-citrate lyase (ACL) inhibitor
EzetimibeCholesterol absorption inhibitor
Clinical data
Trade namesNexlizet, Nustendi
AHFS/Drugs.comMultum Consumer Information
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol.[1][3] It is a combination of bempedoic acid and ezetimibe.[1][2]

The most common side effects are hyperuricemia (high blood levels of uric acid) and constipation.[2]

Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor and ezetimibe is a cholesterol absorption inhibitor.[1] Bempedoic acid works by blocking an enzyme in the liver called adenosine triphosphate citrate lyase, which is involved in making cholesterol.[2] Ezetimibe works by binding to a gut protein called 'Niemann-Pick C1 Like 1', preventing cholesterol from being absorbed into the blood from the gut.[2]

The combination was approved for medical use in the United States in February 2020, and in the European Union in March 2020.[4][2]

  1. ^ a b c d "Nexlizet- bempedoic acid and ezetimibe tablet, film coated". DailyMed. 10 March 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
  2. ^ a b c d e f "Nustendi EPAR". European Medicines Agency (EMA). 29 January 2020. Archived from the original on 22 January 2021. Retrieved 24 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ Pirillo A, Catapano AL (April 2022). "New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia". Current Opinion in Endocrinology, Diabetes, and Obesity. 29 (2): 161–166. doi:10.1097/MED.0000000000000706. PMC 8915986. PMID 34980867.
  4. ^ "Drug Approval Package: Nexlizet". U.S. Food and Drug Administration (FDA). 17 April 2020. Archived from the original on 10 July 2021. Retrieved 24 April 2020.